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The time course of delivery of furosemide into urine: An independent
determinant of overall response. After an oral or intravenous dose of
furosemide, there is considerable interindividual variability in the
amount of unchanged drug delivered into the urine. On average,
approximately half as much reaches the intraluminal site of action with
an oral compared to an intravenous dose. However, the natriuretic
response to the same dose administered by either route is virtually the
same. Similarly, after pretreatment with probenecid, the same total
amount of furosemide in urine causes a greater overall response. It has
been presumed that this paradox is accounted for by differences in rate
of delivery of furosemide to the active site such that after an oral dose,
or after pretreatment with probenecid, amounts of drug are for longer
periods of time at the "steep" portion of the dose-response curve. Our
analysis shows this not to be the case. For furosemide, the "slope
factor" of the dose-response curve is such that the amount of diuretic
delivered into the urine which is maximally efficient (21.5 g/min) is
considerably less than the amount causing half-maximal response (69.8
gImin). Oral administration or pretreatment with probenecid maintains
drug close to this maximally efficient amount more persistently than
does intravenous administration. By so doing, total response to an oral
dose approaches that of intravenous dosing despite delivering half the
amount of drug to the active site, and after probenecid an intravenous
dose causes a greater response than intravenous dosing alone despite
delivering the same amount of drug to the active site. These data
emphasize the importance of the time course of delivery of drug to the
active site as an independent determinant of overall response.
Le temps d'apparition du furosémide dans l'urine: Un facteur indépen-
dant de sa réponse globale. Après administration orale ou intraveineuse
de furosémide il y a des variations interindividuelles considérables dans
Ia quantité de mddicament intact apparaissant dans l'urine. En
moyenne, Ia quantité qui accide au site d'action intraluminale est
réduite de moitié après administration orale par comparaison a l'admin-
istration intraveineuse. Pourtant Ia réponse natriurétique pour une dose
donnée est virtuellement la méme quelle que soit Ia voie d'administra-
tion. De méme, aprés pretraitement avec du probénécide, Ia méme
quantité totale de furosémide urinaire provoque une reponse globale-
ment plus grande. On a suppose que cc paradoxe pouvait étre expliqué
par des differences dans les vitesses d'accession du furosémide a ses
sites actifs, telles qu'après une administration orale, ou après prétraite-
ment avec du probénécide les quantités de mCdicament sont pour des
périodes plus longues a Ia partie "pentue" de Ia courbe dose-réponse.
Notre analyse montre que ce n'est pas le cas. Pour Ic furosdmide Ia
"pente" de Ia courbe dose-réponse est telle que Ia quantité de diuré-
tique délivré dans l'urine ayant une efficacité maximale (21,5 big/mn) est
considérablement plus faible que Ia quantité produisant Ia moitié de Ia
réponse maximale (69,8 p.glmn). L'administration orale ou le prétraite-
ment avec du probénécide maintiennent le mCdicament a une quantité
proche de Ia dose ayant l'efficacité maximale plus longtemps que ne le
fait l'administration intraveineuse. Dc cette facon, la réponse maximale
a une administration orale est proche de celle due a une administration
intraveineuse, malgré l'accession d'une quantité deux fois plus faible de
médicament aux sites actifs. Après probénécide, une administration
intraveineuse induit une réponse plus importante qu'une méme dose
intraveineuse seule, malgré l'accession de Ia méme quantitd de médica-
ment aux sites actifs. Ces données mettent l'accent sur l'importance de
l'accession du médicament a ses sites actifs en fonction du temps. un
facteur indépendant de Ia réponse globale.
In vitro and in vivo animal studies have demonstrated that
furosemide is active from the luminal, or urinary, rather than
the peritubular, or blood, side of the nephron 1—4]. Recently,
this phenomenon has also been demonstrated in man [5, 6]. As a
consequence, by assessing the relationship between delivery of
furosemide into the urine and response, one can probe the
determinants of overall response in man [6—8]. Clearly, the total
amount of drug delivered into the urine is an important determi-
nant. In addition, however, the time course of that delivery has
been shown to influence total response independent of the total
amount of drug reaching the active site [6]. This study reports
our finding of the important role of the "slope factor" of the
dose-response curve in determining the contribution of the time
course of delivery of drug to the overall response to furosemide.
This effect explains two phenomena: (1) our previous observa-
tions that pretreatment of subjects with probenecid causes a
greater overall natriuresis without affecting the total amount of
drug delivered into the urine [6] and (2) oral doses of furosemide
cause the same cumulative natriuretic effect as identical doses
administered intravenously despite delivering only half as much
drug to the active site as the intravenous dose. This finding may
have important general implications regarding design of thera-
peutic strategy or in targeted drug development.
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Methods
Patient data. Data relating delivery of furosemide into urine
and response (quantified as urinary sodium excretion rate) were
derived from 56 separate studies in 21 normal subjects, some of
which have been reported previously as facets of other studies
from this laboratory [6—8]. We administered a 40-mg dose of
furosemide; orally in 21 studies and intravenously over 2-3 mm
in 27 studies; eight subjects also received an intravenous dose
after pretreatment with probenecid sufficient to decrease renal
clearance of furosemide by half [6]. In comparing oral to
Received for publication October 16, 1981
and in revised form January 22, 1982
0085—2538/82/0022—0069 $01.20
© 1982 by the International Society of Nephrology
70 Kaojarern Ct al
intravenous furosemide, analyzing the group in a paired or
unpaired fashion made no difference. Consequently, we used
data from all of the subjects grouped according to mode of
administration. The effects of probenecid were analyzed in a
paired fashion.
Subjects had ingested a diet containing 150 mEq of sodium
and 60 to 80 mEq of potassium per day for 3 days as outpatients
on the General Clinical Research Center. They collected a 24-hr
urine sample beginning the morning of day 3 to assess adher-
ence to the diet. The sodium content of this sample was not
different before any phase of the study.
The study began on the morning of day 4 at the close of the
24-hr urine collection. The day of the study, patients skipped
breakfast (including caffeine containing beverages) but ate
lunch (at least 3 hr after the start of the study).
Heparinized scalp-vein needles were placed in each forearm,
one for administration of furosemide and replacement fluids and
one for obtaining frequent blood samples. All urine was collect-
ed by spontaneous voiding at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24
hr after administration of furosemide. During the first 2 to 3 hr
of the intravenous studies, urine output was replaced by
isovolumic amounts of lactated Ringer's solution administered
by vein over the time interval of the subsequent collection
period. When urine output had decreased to approximately 250
mi/hr. fluids were administered orally. In the oral studies, all
urine losses were replaced by mouth. No changes occurred in
serum sodium, potassium, chloride, or creatinine in any study.
Creatinine clearance did not change throughout the study.
Consequently, we elected to express response as sodium excre-
tion rate in mEq/min.
Assays. Furosemide was measured by high performance
liquid chromatography (HPLC) as previously described [61.
Briefly, urine samples were forced through a O.S-p. filter and 50
p.l of urine were then pipetted into a test tube containing 0.2 ml
water and internal standard. The solution was mixed well and
10 to 20 Ill were injected onto the column. Analyses were
performed with a Waters model ACL-GPC-204 HPLC equipped
with a Waters model 440 dual wavelength detector and a dual
channel 10-mV Omniscribe recorder (Waters Associates, Inc.,
Milford, Massachusetts). The separation was effected with a 30
cm x 4 mm reverse-phase "p. Bondapak C18" column (Waters
Association, Inc.) which was eluted at 2.0 ml per minute with an
acetonitrile/water or methanol/water solution buffered approxi-
mately to pH 3.8 with 0.01 M acetate. Ten determinations of
standard samples at three different concentrations of furose-
mide were 0.0572 0.0015, 0.291 0.002, and 0.896 0.006
for concentrations of approximately 0.06, 0.3, and 0.9 p.g/ml,
respectively.
Sodium was measured with an Instrumentation Laboratories
Model 143 flame photometer.
Pharmacodynarnic analysis. Individual data in each group
were meaned to derive an average relationship between urinary
furosemide and response. This relationship did not differ from
that obtained by analyzing individual data and then meaning the
individual parameters. After the intravenous dose of furose-
mide, a sigmoid-shaped dose-response curve was defined. The
oral dose did not attain sufficient amounts of urinary furosemide
to define the full extent of the curve though those amounts
delivered followed the same dose-response relationship as after
intravenous administration. The dose-response curve was ana-
Furosemide-stimulated sodium 235.1 25.2 359.4 42.9 0.104
excretion, mEq/24 hr
Urinary furosemide excretion, 7.9 1.6 21.2 1.8 0.002
mg/24 hr
Overall efficiency— 29.9
sodium/furosemide, mEq/mg
lyzed using the ALLFIT computer program to fit the curve to a
standard format [9]:
Y-[a-d1- [i+ (x)b]
The model used is the four parameter logistic equation where Y
and X are response and dose, respectively, and a, b, c, and d
are the four derived parameters where a = response at zero
dose, b — "slope factor", c = dose causing half maximal
response (ED50), and d — response at infinite dose or maximal
response.
We elected to use the ratio of response (Y) to dose (X) as a
measure of efficiency. As in the above equation, taking the
derivative of Y/X with respect to X and setting it equal to zero
allows finding the dose which produces maximum efficiency:
X at Maximum Efficiency = [cb(b_l)Il b
(See appendix for more detailed derivation).
Clearly, the maximally efficient dose is a function of the ED0
(c) and the slope factor (b). Consequently, in an attempt to
explain the reasons for greater response relative to delivered
drug. that is. greater overall efficiency of oral compared to
intravenous furosemide, and of intravenous furosemide after
pretreatment with probenecid compared to furosemide alone,
we quantified the relationship between the time course of
amounts of diuretic reaching the urine and the maximally
efficient dose by calculating the cumulative area of deviation of
the time course curve from this value from 0 to 8 hr. Because
the maximally efficient dose was considerably less than the
ED50 (vida infra), we also calculated the areas of deviation from
the ED50 for comparison. Individual areas were derived,
meaned, and compared statistically.
Results
Overall response tofurosemide. Table I quantifies response
to both oral and intravenous doses of furosemide. The consider-
ably smaller amount of furosemide reaching the urine after an
oral dose caused a relatively greater cumulative response
resulting in an overall efficiency (cumulative natriuretic re-
sponse/total amount of furosemide in urine) almost twice that of
the intravenous dose. Figure 1 depicts the time course of the
efficiency of furosemide over 6 hr demonstrating a greater
response relative to dose of the oral formulation throughout the
entire time course of response.
Table 1. Overall response to oral and intravenous furosemide
Basal urinary sodium excretion,
mEqI24 hr
Oral Intravenous P value
123.8 24.5 127.3 -- 15.0 0.907
17.0
Furosetnide response 71
Deviation from
21.5 11/mm
mg
Deviation from
69.8 11/mm
mg
Furosemidei.v. 22.4 8.1 31.6 3.5
(N = 8)
P Value < 0.015 < 0.05
Furosemide i.v. 11.8 4.1 24.4 3.5
plus probenecid(N = 8)
Furosemide i.v. 23.0 7.4 34.5 5.9
(N = 27)
P Value <0.001 NS
Furosemide oral 10.9 7.6 31.4 11.7
(N = 21)
In the paired studies examining the effect of pretreatment
with probenecid, the overall efficiency of furosemide plus
probenecid was 22.4, compared to 13.3 mEq/mg for furosemide
alone. Consequently, both oral administration and pretreatment
with probenecid increased the overall efficiency of furosemide.
Pharmacodynamics of response. Figure 2 depicts dose-re-
sponse curves to both oral and intravenous doses of furosemide
demonstrating that the difference in response cannot be ac-
counted for by the differences in the relationship between
amounts of drug reaching the active site and pharmacologic
effect. A prior publication from this laboratory demonstrated
the same lack of difference in dose-response curves of furose-
mide alone compared to furosemide plus probenecid [61. Com-
puter fitting of the intravenous dose-response curve allowed
derivation of an ED50 (c) of 69.8 15.9 g/min and a slope
factor (b) of 1.23 0.17. From these parameters the dose of
furosemide with maximum efficiency was calculated to be 21.5
p.g/min.
Fig. 2. Dose response curves to oral and to intravenous furosemide.
Symbols are as in Figure I. Derived parameters for the intravenous data
are shown in the figure.
Relationship between route of administration and maximum
efficiency. Figure 3 depicts the time course of urinary furose-
mide excretion after oral and intravenous dosing relative to that
amount of furosemide with maximum efficiency. After oral
administration, amounts of furosemide more persistently ap-
proach that causing maximal efficiency; thereby, during the
summated time course of response, overall natriuresis is greater
relative to total amounts of drug delivered to the active site.
Pretreatment with probenecid caused a counterclockwise shift
in the time course curve with less overall deviation from the
amount with maximum efficiency. Table 2 quantifies cumula-
tive areas of deviation of the different study groups. Oral
administration and pretreatment with probenecid markedly
decreased deviation from the amount of diuretic having maxi-
mum efficiency. In contrast, there was considerably less or no
impact when assessing the relationship of the time course of
delivery to the ED50 of 69.8 sg/min. For furosemide then, the
influence of the time course of delivery of drug to the urinary
site of action on cumulative response is more importantly
related to the derived value with maximum efficiency than to
the ED50 though the former is only one-third the latter.
Effect of the slope factor of the dose-response curve on the
efficiency of furosemide. To further explore the importance of
the slope factor of the dose-response curve on the efficiency of
amounts of furosemide delivered to the active site, we per-
formed computer simulations depicted in Figure 4. For the
subjects in this study (in whom the slope factor equals 1.23),
efficiency increases steeply with increasing delivery of furose-
mide into the urine to a peak efficiency at 21.5 sg/min followed
by a gradual decline. For furosemide then, in normal subjects,
the maximally efficient delivery of drug occurs at a value
considerably less than the ED50 of 69.8 ig/min. As the slope
factor increases, that is, a steeper dose-response curve, the rate
of ascent to maximum efficiency decreases and the peak occurs
at a greater amount of drug. It is important to note that
maximum efficiency will equal the ED50 only when the slope
factor equals 2.0. On the other hand, as the slope factor
decreases, the amount of drug causing maximal efficiency
approaches zero.
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Fig. 1. Time course of the efficiency (sodium excretion/urinary furose-
mide) of oral (solid symbols) versus intravenous (open symbols)
furosemide.
Table 2. Cumulative area (0 to 8 hr) of deviation of the time course of
delivery of furosemide into urine from the amount with maximum
efficiency (21.5 g/min) and from the ED50 (69.8 g/min) (Mean SD)
1 2 3 4 5 6
Time, hours
1 5 10 50 100
Urinary furosemide excretion rate, pg/mm
Fig. 3. Time course of urinary excretion offurosemide after intravenous
(stippled line) and oral (solid line) dosing demonstrating the relation-
ship to the amount of furosemide with maximum efficiency (dashed
line). Shading depicts the areas of deviation quantified and compared
for individual curves (see text and Table 2).
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Fig. 4. Relationship between urinary excretion of furosemide and
efficiency illustrating the influence of the slope factor (b) of the dose-
response curve. The solid line represents data from this study with b =
1.23. The stippled (b = 3) and dashed (b 0.5) lines represent
hypothetical, computer generated lines for a drug with the same ED50 as
furosemide.
Figure 5 depicts the relationship between the slope factor and
amounts of furosemide causing maximal efficiency. For slope
factors less than 2.0, the maximally efficient delivery of furose-
mide is less than the ED50. The maximally efficient amount
peaks with a slope factor of approximately 3 and then gradually
reapproaches the ED50. For furosemide, a maximally efficient
drug delivery never exceeds approximately 95 g/min no matter
what the slope factor. One might then conclude that dosage
regimens delivering greater than these amounts of this diuretic
into the urine may be superfluous.
Fig. 5. Relationship between the slope factor and the urinary excretion
of furosemide having maximal efficiency. The dashed line represents
the ED50 for furosemide of 69.8 jg/min.
Discussion
Though in recent years there has been considerable effort to
delineate the determinants of the natriuretic response to furose-
mide by analyzing both pharniacokinetics and pharmacodynam-
ics in normal subjects and in patients with a variety of diseases,
these determinants are far from well understood [10—131. Our
current analysis adds a heretofore unexplored component;
namely, the importance of the slope factor of the dose-response
curve in determining overall response. Our data with furose-
mide demonstrate that for a drug with a slope factor less than
2.0, a dosing regimen which over the entire time course of
response delivers amounts of drug to the active site with little
deviation from the amount causing maximal efficiency can
result in a greater overall effect relative to total amount of drug
reaching the active site. This phenomenon explains observa-
tions by ourselves and other investigators that oral doses of
furosemide cause considerably greater response relative to drug
delivered to the urinary site of action compared to intravenous
dosing.
Branch et al studied the effect of 80 mg of furosemide orally
versus intravenously in six normal volunteers [12]. Urinary
sodium after 36 hr was not significantly different (203 10 mEq
orally versus 238 16 mEq iv.), but furosemide recovery in
urine over the same period was 25 2.9 mg for oral and 52
3.8 mg for intravenous administration (P < 0.05). Kelly et al
compared the response between different formulations and
routes of administration of 80 mg of furosemide to eight normal
volunteers [14]. They also found no significant difference in the
sodium excretion 12 hr after oral (578 90.6 mEq) versus
intravenous administration (600.3 79.5 mEq), while the oral
bioavailability of drug was approximately half that after intrave-
nous administration (P < 0.005).
These previous investigators, including ourselves, attributed
this phenomenon to the oral route of administration's providing
amounts of drug at the "steep" portion of the dose-response
curve for greater periods of time than did the intravenous route.
This hypothesis was conjectural. The current analysis demon-
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strates the principle to be correct but emphasizes the impor-
tance of the maximally efficient dose and its determination by
the slope factor of the dose-response curve.
Overall response to a diuretic is determined by delivery of
drug to its site of action, delivery of solute to the site of action,
the dynamics of interaction of drug with its receptor and
whether or not solute is reclaimed distal to the site of action
[151. Because dose-response curves to furosemide were identi-
cal with all dosing regimens (Fig. 2) [61, there is no evidence
that any of the aforementioned factors can account for the
differences in overall response relative to drug delivery ob-
served with the different dosing regimens.
To probe the mechanism of this seeming paradox, we used
the concept of the ratio of sodium to furosemide excretion to
describe the efficiency of the diuretic. This ratio has been used
by others, though in a somewhat different context, to describe
the influence of indomethacin on the response to furosemide in
the dog [161 and to describe the interaction between probenecid
or spironolactone and furosemide in man [17]. Applying this
efficiency approach to the actual dose-response curve to furose-
mide allowed mathematical derivation of the determinants of
maximum efficiency which, in turn, allowed comparison be-
tween dosing regimens in terms of the relationship between the
actual time course of delivery of drug to the active site and that
amount of drug with maximal efficiency. Analyzing the data in
this fashion indicated that the oral route of administration and
pretreatment with probenecid provided amounts of drug close
to the maximally efficient level more persistently than did the
intravenous route (Fig. 3), thereby accounting for the overall
greater efficiency of the oral dose with virtually identical
natriuresis as the intravenous dose despite delivering only half
as much total drug to the site of action.
It was surprising for us to discover the critical role of the
slope factor of the dose-response curve in determining the
maximally efficient dose. In fact, we have been unable to find
any literature addressing this relationship, a concept applicable
to all drugs [18, 19]. Importantly, for a slope factor less than 2.0,
the maximally efficient dose is less than the ED50. It is
conceivable that one may wish to design therapeutic regimens
of many drugs having low slope factors such that the goal is
maintenance of maximally efficient amounts at the active site
for prolonged periods of time. By so doing one could accom-
plish the same or perhaps greater cumulative effect with less
total drug and at lower peak drug concentrations. During
targeted drug development, one might actually select agents
with low rather than high slope factors depending on the
therapeutic goal.
In summary, analysis of the importance of the slope factor of
the dose-response curve in determining the amount of any drug
which is maximally efficient allowed clarification of a seeming
paradox regarding overall response to different formulations of
furosemide. This concept may have potential importance for
design of therapeutic regimens and in drug development.
Appendix
The relationship between response (Y) and dose (X) can be
expressed as
Y=[a—d]± [+ (x)b]
where a is response at a dose of zero, b is the "slope factor", c
is the dose causing half-maximal response, and d is the maximal
response or response at infinite dose.
As a approaches zero or becomes negligible related to d, the
equation reduces to
Y=—d÷ [i+ (x)b]
Dividing both sides of the equation by X and rearranging
defines efficiency (response/dose):
Taking the first derivative with respect to X and setting this
derivative equal to zero allows derivation of the dose with
maximum efficiency:
X at Maximum Efficiency = [cb (b —
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